Johnson & Johnson · Healthcare
Survives a correction-sized 3-point cut to analyst growth.
At a 26.0% margin the price requires 2.2% 3y revenue CAGR against 7.5% consensus, a cushion of +5.6pt versus a 0pt correction cut. Cushion clears the cut, so the price survives the correction on consensus estimates. Defensive; no cut.
Breaks if: talc charges recur at scale. We re-check this against analyst estimates every evening.
10 years, at a 26% margin (analysts' margin, cut for cash conversion)
+5.5%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
15 published targets
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 89% of reported profit arrived as operating cash, so the test cuts the analysts' 29% margin to 26%. That leaves a cushion of +5pt instead of +8pt, and the smaller of the two decides the group.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Nov 21, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price of the price sits within 4% of the median of 15 published models ($270-$320, median $282), so the market is paying for the consensus story — the $320 bull cases (HSBC, UBS at +18%) are the published upside it declines to pay.
Can Innovative Medicine accelerate materially above the delivered 6% (via Carvykti scaling, the Stelara hole being refilled, and new launches) enough to justify the +12.8% growth the reverse-DCF requires — the answer is investigable through segment revenue history (unit_volumes), which is wired, so YES it can be measured.
A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names